Nuvectis Pharma (NVCT) Q2 2026 earnings summary

Executive summary

• Focused on developing precision medicines for complement-related conditions and oncology, with three main clinical-stage candidates: NXP100 (ciprocopan), NXP200, and NXP900.

• In-licensed exclusive worldwide rights (excluding certain territories) to NXP100 and NXP200 from Haisco, transforming into a late-stage clinical development organization.

• Ciprocopan (NXP100) approved in China for PNH patients not previously treated with complement inhibitors.

• No commercial products or revenue to date; operations funded primarily through equity offerings.

Financial highlights

• Cash and cash equivalents were $22.2 million as of June 30, 2026, down from $31.6 million at year-end 2025.

• Net loss for Q2 2026 was $7.0 million, compared to $6.3 million in Q2 2025; net loss for the first half of 2026 was $13.1 million, up from $11.7 million year-over-year.

• Research and development expenses rose to $4.7 million in Q2 2026 from $3.6 million in Q2 2025, mainly due to higher manufacturing, clinical trial, and employee costs.

• General and administrative expenses decreased by 16% in Q2 2026 versus Q2 2025, mainly due to lower professional and consulting fees.

• Finance income was $0.2 million in Q2 2026, down from $0.3 million in Q2 2025.

Outlook and guidance

• Proceeds from a July 2026 public offering ($106.3 million net, $115 million gross) are expected to fund operations for at least 12 months and extend the cash runway into 1H 2029.

• U.S. IND submissions for ciprocopan (NXP100) and NXP200 expected in 4Q2026.

• NXP900 clinical development to focus on combination therapies in NSCLC and pancreatic cancer, with trial updates expected by year-end and new study initiations in 3Q2026.

• Anticipates increased expenses as clinical programs advance and additional personnel are hired.

• Long-term viability depends on raising additional capital to complete clinical trials and pursue regulatory approvals.